Reneuron Group PLC operates in the Commercial physical research sector. ReNeuron Group Plc (ReNeuron) is engaged in clinical-stage stem cell business. The Company is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. It used its stem cell technologies to develop cellbased therapies for disease conditions where the cells can be readily administered off-the-shelf to any eligible patient without the need for additional drug treatments. Its lead therapeutic candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. It is also developing stem cell therapies for other conditions, such as peripheral arterial disease and blindness-causing diseases of the retina. It has a range of stem cell lines for non-therapeutic applications. Its ReNcell products are used in academic and commercial research. Its ReNcellCX and ReNcellVM neural cell lines are marketed globally. In our complete report available for purchase the company is compared to: Futura Medical PLC, Mologen AG and Eden Research PLC.